Codipilly DC, et al
Oshiro K, Koizumi M, Maruyama H, et al
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential
Transitioning from semaglutide to retatrutide If you are currently on semaglutide , the transition involves stopping semaglutide and allowing a washout period before starting the retatrutide dose schedule
Osteoarthritis pain signal WOMAC pain scores fell by up to 4.5 points, equivalent to a 75.8% relative reduction in pain from baseline
Discussing this potential benefit with both your neurologist and your metabolic physician is worthwhile